Related Experiment Videos
The Future of Targeting FLT3 Activation in AML
1Department of Medicine, Johns Hopkins University, 600 North Wolfe Street, Harvey 805, Baltimore, MD, 21287, USA.
Abstract:
Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets, and FLT3 tyrosine-kinase inhibitors (TKIs) have been in development for the last decade with steadily increasing potency. However, FLT3-mutated AML often acquires resistance to the growing armamentarium of FLT3 inhibitors through a variety of mechanisms. In this review, we discuss the distinct clinical phenotype of FLT3-mutated AML, historically and currently available therapeutics, mechanisms of resistance, ongoing trials, and future outlook at treatment strategies.
Insights
FMS-like tyrosine-kinase 3 (FLT3) mutations in acute myeloid leukemia (AML) are poor prognostic markers. This review covers FLT3-mutated AML treatments, resistance mechanisms, and future therapeutic strategies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- FMS-like tyrosine-kinase 3 (FLT3) mutations, including internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations, are present in up to one-third of acute myeloid leukemia (AML) patients.
- These mutations are associated with a poor prognosis in AML.
- FLT3 mutations have been recognized as critical therapeutic targets for over a decade.
Purpose of the Study:
- To review the clinical characteristics of FLT3-mutated AML.
- To discuss the evolution of FLT3 tyrosine-kinase inhibitors (TKIs) and their efficacy.
- To explore mechanisms of resistance to FLT3 inhibitors and outline future treatment strategies.
Main Methods:
- This review synthesizes information from preclinical studies and clinical trials.
- It analyzes data on the efficacy and resistance patterns of various FLT3 inhibitors.
- The review discusses ongoing research and clinical trials in FLT3-mutated AML.
Main Results:
- FLT3-mutated AML presents a distinct clinical phenotype.
- FLT3 inhibitors have shown increasing potency but are often overcome by resistance mechanisms.
- Acquired resistance to FLT3 inhibitors is a significant clinical challenge.
Conclusions:
- Despite advancements in FLT3 inhibitor development, resistance remains a major hurdle in treating FLT3-mutated AML.
- Understanding resistance mechanisms is crucial for developing novel therapeutic approaches.
- Future strategies will likely involve combination therapies and next-generation inhibitors to overcome resistance and improve patient outcomes.